With this issue, The Journal of Pharmacology and Experimental Therapeutics launches a new feature and resurrects an old one. The new offering, “Perspectives in Pharmacology”, is a series of brief reviews covering new and emerging topics in biomedical research of particular relevance to pharmacologists. These articles, authored by experts in the field, are solicited by invitation only and are peer reviewed to ensure accuracy, balance, and a quality presentation. The associate editors of the journal are responsible for identifying topics and authors and for inviting contributions. Unsolicited submissions to Perspectives in Pharmacology will not be considered for publication. The Perspectives in Pharmacology are designed to appeal to a broad audience in an effort to inform those not working directly in the covered area and to serve as a primary resource for individuals undertaking a literature search on the topic. The first of these reviews, “GABAB Receptors: First of the Metabotropic Heterodimers”, appears in this issue. In the coming months, reviews will be published on neuronal nicotinic receptors, histamine receptors and myocardial ischemia, G protein-coupled receptor signaling, and the role of phospholipases in cell injury and death, among others. Outside of Perspectives in Pharmacology, the journal will publish annually a review authored by the recipient of the Otto Krayer award and, biennially, an article by the Torald Sollmann awardee. In addition, the journal will on occasion publish reports summarizing the proceedings of selected symposia and colloquia sponsored by the American Society for Pharmacology and Experimental Therapeutics. As for the old feature, regular readers will notice that, once again, articles are divided under area headings in the table of contents. Although such designations were discarded in the past due to the difficulties associated with assigning manuscripts to a single subdiscipline, this format has been reinstated in response to popular demand. The publication of review articles is intended to supplement, not replace, the research reports authored by individual investigators that have been the mainstay ofJPET for the past century. It is hoped this new feature will provide a valuable service to our readers by enhancing further the utility of the journal as a major repository for information on the current trends, latest developments, and new opportunities in the field.
- The American Society for Pharmacology and Experimental Therapeutics